27333594|t|Proteomic analysis of docetaxel resistance in human nasopharyngeal carcinoma cells using the two-dimensional gel electrophoresis method
27333594|a|Docetaxel -based chemotherapy has been recommended for advanced nasopharyngeal carcinoma (NPC). However, treatment failure often occurs because of acquired drug resistance. In this study, a docetaxel - resistant NPC cell line CNE-2R was established with increasing doses of docetaxel for more than 6 months. Two-dimensional gel electrophoresis and ESI-Q-TOF-MS were used to compare the differential expression of docetaxel - resistance - associated proteins between human NPC CNE-2 cells and docetaxel - resistant CNE-2R cells. As a result, 24 differentially expressed proteins were identified, including 11 proteins with increased expression and 13 proteins with decreased expression. These proteins function in diverse biological processes such as metabolism, signal transduction, calcium ion binding, immune response, proteolysis, and so on. Among these, α-enolase (ENO1), significantly upregulated in CNE-2R, was selected for detailed analysis. Inhibition of ENO1 by shRNA restored CNE-2R cells ' sensitivity to docetaxel. Moreover, overexpression of ENO1 could facilitate the development of acquired resistance of docetaxel in CNE-2 cells. Western blot and reverse-transcription PCR data of clinical samples confirmed that α-enolase was upregulated in docetaxel - resistant human NPC tissues. Finding such proteins might improve interpretation of the molecular mechanisms leading to the acquisition of docetaxel chemoresistance.
27333594	0	9	Proteomic	T091	C0872252
27333594	10	18	analysis	T062	C0936012
27333594	22	31	docetaxel	T109,T121	C0246415
27333594	32	42	resistance	T038	C0013203
27333594	46	51	human	T016	C0086418
27333594	52	76	nasopharyngeal carcinoma	T191	C2931822
27333594	77	82	cells	T025	C0597032
27333594	93	135	two-dimensional gel electrophoresis method	T059	C0013860
27333594	136	145	Docetaxel	T109,T121	C0246415
27333594	153	165	chemotherapy	T061	C3665472
27333594	175	186	recommended	T078	C0034866
27333594	200	224	nasopharyngeal carcinoma	T191	C2931822
27333594	226	229	NPC	T191	C2931822
27333594	241	258	treatment failure	T033	C0162643
27333594	283	291	acquired	T080	C0439661
27333594	292	307	drug resistance	T038	C0013203
27333594	317	322	study	T062	C0681814
27333594	326	335	docetaxel	T109,T121	C0246415
27333594	338	347	resistant	T038	C0013203
27333594	348	351	NPC	T191	C2931822
27333594	352	368	cell line CNE-2R	T025	C0085983
27333594	373	384	established	T080	C0443211
27333594	390	400	increasing	T169	C0442808
27333594	401	406	doses	T081	C0178602
27333594	410	419	docetaxel	T109,T121	C0246415
27333594	424	433	more than	T081	C0439093
27333594	436	442	months	T079	C0439231
27333594	444	479	Two-dimensional gel electrophoresis	T059	C0013860
27333594	484	496	ESI-Q-TOF-MS	T059	C0599827
27333594	510	517	compare	T052	C1707455
27333594	535	545	expression	T045	C1171362
27333594	549	558	docetaxel	T109,T121	C0246415
27333594	561	571	resistance	T038	C0013203
27333594	574	593	associated proteins	T116,T123	C0033684
27333594	602	607	human	T016	C0086418
27333594	608	611	NPC	T191	C2931822
27333594	612	623	CNE-2 cells	T025	C0007634
27333594	628	637	docetaxel	T109,T121	C0246415
27333594	640	649	resistant	T038	C0013203
27333594	650	662	CNE-2R cells	T025	C0007634
27333594	669	675	result	T033	C2825142
27333594	680	694	differentially	T080	C0443199
27333594	695	713	expressed proteins	T045	C1171362
27333594	719	729	identified	T080	C0205396
27333594	744	752	proteins	T116,T123	C0033684
27333594	758	767	increased	T081	C0205217
27333594	768	778	expression	T045	C1171362
27333594	786	794	proteins	T116,T123	C0033684
27333594	800	809	decreased	T081	C0205216
27333594	810	820	expression	T045	C1171362
27333594	828	845	proteins function	T044	C1527118
27333594	849	856	diverse	T080	C1880371
27333594	857	877	biological processes	T038	C3714634
27333594	886	896	metabolism	T169	C0025520
27333594	898	917	signal transduction	T043	C0037083
27333594	919	938	calcium ion binding	T044	C1148580
27333594	940	955	immune response	T042	C0301872
27333594	957	968	proteolysis	T044	C0597304
27333594	994	1003	α-enolase	T116,T126	C2364020
27333594	1005	1009	ENO1	T116,T126	C2364020
27333594	1041	1047	CNE-2R	T025	C0007634
27333594	1053	1061	selected	T052	C1707391
27333594	1075	1083	analysis	T062	C0936012
27333594	1085	1095	Inhibition	T052	C3463820
27333594	1099	1103	ENO1	T116,T126	C2364020
27333594	1107	1112	shRNA	T114	C2930586
27333594	1122	1134	CNE-2R cells	T025	C0007634
27333594	1137	1148	sensitivity	T169	C0332324
27333594	1152	1161	docetaxel	T109,T121	C0246415
27333594	1173	1187	overexpression	T045	C1514559
27333594	1191	1195	ENO1	T116,T126	C2364020
27333594	1217	1228	development	T169	C1527148
27333594	1232	1240	acquired	T080	C0439661
27333594	1241	1251	resistance	T038	C0013203
27333594	1255	1264	docetaxel	T109,T121	C0246415
27333594	1268	1279	CNE-2 cells	T025	C0007634
27333594	1281	1293	Western blot	T059,T063	C0005863
27333594	1298	1323	reverse-transcription PCR	T063	C0599161
27333594	1324	1328	data	T078	C1511726
27333594	1332	1348	clinical samples	T077	C2347026
27333594	1349	1358	confirmed	T080	C0521093
27333594	1364	1373	α-enolase	T116,T126	C2364020
27333594	1393	1402	docetaxel	T109,T121	C0246415
27333594	1405	1414	resistant	T038	C0013203
27333594	1415	1420	human	T016	C0086418
27333594	1421	1424	NPC	T191	C2931822
27333594	1425	1432	tissues	T024	C0040300
27333594	1434	1441	Finding	T033	C0243095
27333594	1447	1455	proteins	T116,T123	C0033684
27333594	1462	1469	improve	T033	C0184511
27333594	1470	1484	interpretation	T170	C0459471
27333594	1492	1512	molecular mechanisms	T044	C3537153
27333594	1513	1520	leading	T169	C1522538
27333594	1528	1539	acquisition	T052	C1706701
27333594	1543	1552	docetaxel	T109,T121	C0246415
27333594	1553	1568	chemoresistance	T038	C0013203